Significance of brain lesions in parkinson disease dementia and lewy body dementia

Frontiers of Neurology and Neuroscience

Volumn 24, Issue , 2009, Pages 114-125

  Jellinger, Kurt A ^a  

^a INSTITUTE OF CLINICAL NEUROBIOLOGY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; TAU PROTEIN;

ALZHEIMER DISEASE; AUTOPSY; BRAIN DAMAGE; BRAIN STEM; CEREBROVASCULAR DISEASE; CLINICAL FEATURE; COGNITIVE DEFECT; CORTICOBASAL DEGENERATION; DIFFUSE LEWY BODY DISEASE; DISEASE DURATION; DISEASE SEVERITY; GLOBUS PALLIDUS; HUMAN; IMMUNOHISTOCHEMISTRY; INCIDENCE; NEUROPATHOLOGY; PARKINSON DISEASE; PARKINSONISM; PREVALENCE; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; REVIEW; SHY DRAGER SYNDROME; VASCULAR AMYLOIDOSIS; BRAIN; DEMENTIA; PATHOLOGY;

BRAIN; DEMENTIA; HUMANS; LEWY BODY DISEASE; PARKINSON DISEASE;

EID: 65349177873     PISSN: 16604431     EISSN: 16622804     Source Type: Book Series    
DOI: 10.1159/000197890     Document Type: Review

References (54)

1. Braak H, Sastre M, Bohl JR, de Vos RA, Del Tredici K: Parkinson's disease: lesions in dorsal horn layer I, involvement of parasympathetic and sympathetic pre- and postganglionic neurons. Acta Neuropathol 2007;113:421-429.
2. Jellinger KA: Morphological substrates of Parkinsonism with and without dementia. A retrospective clinico-pathological study. J Neural Transm 2007;(suppl 72):91-104.
3. McKeith IG, Dickson DW, Lowe J, et al: Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005;65:1863-1872.
4. Dubois B, Burn D, Goetz C, Aarsland D, Brown RG, Broe GA, Dickson D, Duyckaerts C, Cummings J, Gauthier S, Korczyn A, Lees A, Levy R, Litvan I, Mizuno Y, McKeith IG, Olanow C W, Poewe W, Sampaio C, Tolosa E, Emre M: Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force. Mov Disord 2007;22:2314-2324.
5. Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, Broe GA, Cummings J, Dickson DW, Gauthier S, Goldman J, Goetz C, Korczyn A, Lees A, Levy R, Litvan I, McKeith I, Olanow W, Poewe W, Quinn N, Sampaio C, Tolosa E, Dubois B: Clinical diagnostic criteria for dementia associated with Parkinsons disease. Mov Disord 2007;22:1689-1707
6. Alafuzoff I, Parkkinen L, Al-Sarraj S, et al: Assessment of α-synuclein pathology: a study of the BrainNet Europe Consortium. J Neuropathol Exp Neurol 2008;67:125-143.
7. Zaccai J, McCracken C, Brayne C: A systematic review of prevalence and incidence studies of dementia with Lewy bodies. Age Ageing 2005;34: 561-566.
8. Jellinger KA, Attems J: Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease. Acta Neuropathol 2008;115:427-436.
9. Caballol N, Marti MJ, Tolosa E: Cognitive dysfunction and dementia in Parkinson disease. Mov Disord 2007;(suppl 17):S358-S366.
10. Ziabreva I, Ballard CG, Aarsland D, Larsen JP McKeith IG, Perry RH, Perry EK: Lewy body disease: thalamic cholinergic activity related to dementia and parkinsonism. Neurobiol Aging 2006;27: 433-438.
11. Fujita M, Ichise M, Zoghbi SS, Liow JS, Ghose S, Vines DC, Sangare J, Lu JQ, Cropley VL, Iida H, Kim KM, Cohen RM, Bara-Jimenez W, Ravina B, Innis RB: Widespread decrease of nicotinic acetylcholine receptors in Parkinsons disease. Ann Neurol 2006;59:174-177.
12. Kramer ML, Schulz-Schaeffer WJ: Presynaptic α-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. J Neurosci 2007;27:1405-1410.
13. Galpern WR, Lang AE: Interface between tauopa-thies and synucleinopathies: a tale of two proteins. Ann Neurol 2006;59:449-458.
14. Lashley T, Holton JL, Gray E, Kirkham K, O'Sullivan SS, Hilbig A, Wood NW, Lees AJ, Revesz T: Cortical α-synuclein load is associated with amyloid-fi plaque burden in a subset of Parkinsons disease patients. Acta Neuropathol 2008;115:417-425.
15. Mandal PK, Pettegrew JW, Masliah E, Hamilton RL, Mandal R: Interaction between Aβ peptide and a synuclein: molecular mechanisms in overlapping pathology of Alzheimer's and Parkinsons in dementia with Lewy body disease. Neurochem Res 2006; 31:1153-1162.
16. Jellinger KA: Lewy body disorders; in Youdin MBH, Riederer P, Mandel SA, Battistin L, Lajtha A (eds): Degenerative Diseases of the Nervous System. New York, Springer Science, 2007, pp 267-343.
17. Mattila PM, Rinne JO, Helenius H, Dickson DW, Roytta M: α-Synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinsons disease. Acta Neuropathol 2000; 100:285-290.
18. Apaydin H, Ahlskog JE, Parisi JE, Boeve BF, Dickson DW: Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. Arch Neurol 2002;59:102-112.
19. Hurtig HI, Trojanowski JQ, Galvin J, Ewbank D, Schmidt ML, Lee VM, Clark CM, Glosser G, Stern MB, Gollomp SM, Arnold SE: α-Synuclein cortical Lewy bodies correlate with dementia in Parkinsons disease. Neurology 2000;54:1916-1921.
20. Kövari E, Gold G, Herrmann FR, Canuto A, Hof PR, Bouras C, Giannakopoulos P: Lewy body densities in the entorhinal and anterior cingulate cortex predict cognitive deficits in Parkinsons disease. Acta Neuropathol (Berl) 2003;106:83-88.
21. Mattila PM, Rinne JO, Helenius H, Roytta M: Neuritic degeneration in the hippocampus and amygdala in Parkinsons disease in relation to Alzheimer pathology. Acta Neuropathol (Berl) 1999; 98:157-164.
22. Harding AJ, Halliday GM: Cortical Lewy body pathology in the diagnosis of dementia. Acta Neuropathol 2001;102:355-363.
23. Braak H, Rub U, Jansen Steur EN, Del Tredici K, de Vos RA: Cognitive status correlates with neuro-pathologic stage in Parkinson disease. Neurology 2005;64:1404-1410.
24. Colosimo C, Hughes AJ, Kilford L, Lees AJ: Lewy body cortical involvement may not always predict dementia in Parkinsons disease. J Neurol Neurosurg Psychiatry 2003;74:852-856.
25. Weisman D, Cho M, Taylor C, Adame A, Thal LJ, Hansen LA: In dementia with Lewy bodies, Braak stage determines phenotype, not Lewy body distribution. Neurology 2007;69:356-359.
26. Jellinger KA: Re: in dementia with Lewy bodies, Braak stage determines phenotype, not Lewy body distribution. Neurology 2008;70:407-408.
27. Deramecourt V, Bombois S, Maurage CA, Ghestem A, Drobecq H, Vanmechelen E, Lebert F, Pasquier F, Delacourte A: Biochemical staging of synucleinopa-thy and amyloid deposition in dementia with Lewy bodies. J Neuropathol Exp Neurol 2006;65:278-288.
28. Ramirez-Ruiz B, Marti MJ, Tolosa E, Bartres-Faz D, Summerfield C, Salgado-Pineda P, Gomez-Anson B, Junque C: Longitudinal evaluation of cerebral morphological changes in Parkinsons disease with and without dementia. J Neurol 2005;252:1345-1352.
29. Pedersen KM, Marner L, Pakkenberg H, Pakkenberg B: No global loss of neocortical neurons in parkin-sons disease: a quantitative stereological study. Mov Disord 2005;20:164-171.
30. Mastaglia FL, Johnsen RD, Byrnes ML, Kakulas BA: Prevalence of amyloid-beta; deposition in the cerebral cortex in Parkinsons disease. Mov Disord 2003;18: 81-86.
31. Thomas A, Ballard C, Kenny RA, O'Brien J, Oakley A, Kalaria R: Correlation of entorhinal amyloid with memory in Alzheimer's and vascular but not Lewy body dementia. Dement Geriatr Cogn Disord 2005; 19:57-60.
32. Maetzler W, Reimold M, Liepelt I, Solbach C, Leyhe T, Schweitzer K, Eschweiler GW, Mittelbronn M, Gaenslen A, Uebele M, Reischl G, Gasser T, Machulla HJ, Bares R, Berg D: [11C]PIB binding in Parkinson's disease dementia. Neuroimage 2008;39: 1027-1033.
33. Edison P, Rowe CC, Rinne JO, Ng S, Ahmed I, Kemppainen N, Villemagne VL, O'Keefe G, Nagren K, Chaudhuri R, Masters CL, Brooks DJ: Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB-PET. J Neurol Neurosurg Psychiatry 2008; in press.
34. Gomperts SN, Rentz DM, Moran E, Becker JA, Locascio JJ, Klunk WE, Mathis CA, Elmaleh DR Shoup T, Fischman AJ, Hyman BT, Growdon JH, Johnson KA: Imaging amyloid deposition in Lewy body diseases. Neurology 2008;71:903-910.
35. Bertrand E, Lewandowska E, Pasennik E, Stepien T, Szpak GM, Dymecki J, Wierzba-Bobrowicz T: Cerebral amyloid angiopathy in idiopathic Parkinson's disease. Acta Neuropathol 2007;114: 308.
36. Burton EJ, McKeith IG, Burn DJ, O'Brien JT: Brain atrophy rates in Parkinson's disease with and without dementia using serial magnetic resonance imaging. Mov Disord 2005;20:1571-1576.
37. Camicioli R, Moore MM, Kinney A, Corbridge E, Glassberg K, Kaye JA: Parkinson's disease is associated with hippocampal atrophy. Mov Disord 2003; 18:784-790.
38. Tam CW, Burton EJ, McKeith IG, Burn DJ, O'Brien JT: Temporal lobe atrophy on MRI in Parkinson disease with dementia: a comparison with Alzheimer disease and dementia with Lewy bodies. Neurology 2005;64:861-865.
39. Dickson DW: Neuropathology and pathogenesis of dementia with Lewy bodies; in O'Brien J, Ames D, McKeith I, Chiu E (eds): Dementia with Lewy Bodies and Parkinson's Disease Dementia. London, Taylor & Francis, 2006, pp 149-166.
40. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E: Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197-211.
41. Jellinger KA, Attems J: Does striatal pathology distinguish Parkinson disease with dementia and dementia with Lewy bodies? Acta Neuropathol 2006;112:253-260.
42. Kalaitzakis ME, Graeber MB, Gentleman SM, Pearce RK: Striatal β -amyloid deposition in Parkinson disease with dementia. J Neuropathol Exp Neurol 2008.
43. Hansen L, Salmon D, Galasko D, Masliah E, Katzman R, DeTeresa R, Thal L, Pay MM, Hofstetter R, Klauber M, et al: The Lewy body variant of Alzheimer's disease: a clinical and pathologic entity. Neurology 1990;40:1-8.
44. Perneczky R, Mosch D, Neumann M, Kretzschmar H, Muller U, Busch R, Forstl H, Kurz A: The Alzheimer variant of Lewy body disease: a pathologically confirmed case-control study. Dement Geriatr Cogn Disord 2005;20:89-94.
45. Uchikado H, Lin WL, DeLucia MW, Dickson DW: Alzheimer disease with amygdala Lewy bodies: a distinct form of α-synucleinopathy J Neuropathol Exp Neurol 2006;65:685-697.
46. Ballard C, Ziabreva I, Perry R, Larsen JP, O'Brien J, McKeith I, Perry E, Aarsland D: Differences in neu-ropathologic characteristics across the Lewy body dementia spectrum. Neurology 2006;67:1931-1934.
47. Giasson BI, Covy JP, Bonini NM, Hurtig HI, Farrer MJ, Trojanowski JQ, Van Deerlin VM: Biochemical and pathological characterization of Lrrk2. Ann Neurol 2006;59:315-322.
48. Duka T, Rusnak M, Drolet RE, Duka V, Wersinger C, Goudreau JL, Sidhu A: α-Synuclein induces hyperphosphorylation of Tau in the MPTP model of parkinsonism. FASEB J 2006;20:2302-2312.
49. Shao CY, Crary JF, Rao C, Sacktor TC, Mirra SS: Atypical protein kinase C in neurodegenerative disease II: PKCiota/lambda in tauopathies and α-synu-cleinopathies. J Neuropathol Exp Neurol 2006;65: 327-335.
50. Giasson BI, Forman MS, Higuchi M, Golbe LI, Graves CL, Kotzbauer PT, Trojanowski JQ, Lee VM: Initiation and synergistic fibrillization of tau and α-synuclein. Science 2003;300:636-640.
51. Soto C, Estrada LD: Protein misfolding and neuro-degeneration. Arch Neurol 2008;65:184-189.
52. Pletnikova O, West N, Lee MK, Rudow GL, Skolasky RL, Dawson TM, Marsh L, Troncoso JC: Aβ deposition is associated with enhanced cortical α-synuclein lesions in Lewy body diseases. Neurobiol Aging 2005;26:1183-1192.
53. Obi K, Aklyama H, Kondo H, Shimomura Y, Hasegawa M, Iwatsubo T, Mizuno Y, Mochizuki H: Relationship of phosphorylated α-synuclein and tau accumulation to Aβ deposition in the cerebral cortex of dementia with Lewy bodies. Exp Neurol 2008;210:409-420.
54. Peuralinna T, Oinas M, Polvikoski T, Paetau A, Sulkava R, Niinisto L, Kalimo H, Hernandez D, Hardy J, Singleton A, Tienari PJ, Myllykangas L: Neurofibrillary tau pathology modulated by genetic variation of α-synuclein. Ann Neurol 2008;64:348-352.